Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05188170 · ClinicalTrials.gov registry record · Phase 1
Niclosamide in Pediatric Patients With Relapsed and Refractory AML
A Phase 1 study of Acute Myeloid Leukemia (AML), sponsored by Stanford University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT05188170 is a Phase 1 study of Acute Myeloid Leukemia (AML) that is actively recruiting participants, run by Stanford University. The registered enrollment target is 16 participants, below the 145-participant average among 29 other Acute Myeloid Leukemia (AML) trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05188170, a Phase 1 study of Acute Myeloid Leukemia (AML), is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
Protocol is designed to evaluate a niclosamide dose escalation scale in combination with cytarabine as a therapeutic modality for pediatric subjects with relapsed/refractory acute myeloid leukemia.
Conditions Studied
Interventions
- DRUG Niclosamide
Study Locations (1)
California
- Stanford University - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2022-11-21 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05188170
The ClinicalTrials.gov registry entry for NCT05188170 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 145-participant average among 29 other Acute Myeloid Leukemia (AML) trials with a reported enrollment target (89% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Myeloid Leukemia (AML) appearing as the primary indexed condition, and to 1 intervention - of which Niclosamide is the first listed.
NCT05188170 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05188170 about?
NCT05188170 is a clinical study titled "Niclosamide in Pediatric Patients With Relapsed and Refractory AML". Protocol is designed to evaluate a niclosamide dose escalation scale in combination with cytarabine as a therapeutic modality for pediatric subjects with relapsed/refractory acute myeloid leukemia.
What is the current status of trial NCT05188170?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2022-11-21. Estimated completion is 2026-12.
What conditions does trial NCT05188170 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia (AML).
What interventions are being tested in trial NCT05188170?
The interventions under investigation include: Niclosamide (DRUG).
Who is sponsoring clinical trial NCT05188170?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05188170 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia (AML)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)
RECRUITING · Phase 1
-
APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
RECRUITING · Phase 1
-
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
RECRUITING · Phase 1
-
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
RECRUITING · Phase 1
-
A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia
ACTIVE NOT RECRUITING · Phase 1
-
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.